Bell Investment Advisors’s Janux Therapeutics JANX Stock Holding History

Bell Investment Advisors’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.92K	Buy	+138	New	+$1.89K	﹤0.01%	1350

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bell Investment Advisors's JANX Position: Q1 2026 in Review

Bell Investment Advisors opened a new position in Janux Therapeutics (JANX) in Q1 2026: 138 shares worth $1.92K. The stake represents ﹤0.01% of the portfolio and ranks #1350 among its holdings.

190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

Bell Investment Advisors held 138 shares of Janux Therapeutics worth $1.92K as of Q1 2026.
Janux Therapeutics was a new Bell Investment Advisors position in Q1 2026.
Janux Therapeutics made up ﹤0.01% of Bell Investment Advisors's portfolio in Q1 2026, its #1350 holding.
190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Bell Investment Advisors's 13F filing for Q1 2026, filed 17 Apr 2026.